Dr. Till on the Utility of Brexucabtagene Autoleucel in MCL

Partner | Cancer Centers | <b>SCCA</b>

Brian Till, MD, discusses the utility of brexucabtagene autoleucel in mantle cell lymphoma.

Brian Till, MD, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the utility of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma (MCL).

In July 2020, brexucabtagene autoleucel received FDA approval for the treatment of patients with relapsed/refractory MCL based on findings from the phase 2 ZUMA-2 trial, in which the CAR T-cell product elicited an 87% objective response rate in this patient population.

Updated follow-up data from the study, which were presented during the 47th Annual Meeting of the EBMT, demonstrated significant and durable responses, as well as a reduction in adverse effects, with brexucabtagene autoleucel in this patient population.

Essentially, brexucabtagene autoleucel utilizes the same manufacturing construct as axicabtagene ciloleucel (axi-cel; Yescarta); however, brexucabtagene autoleucel has an added selection step to remove circulating leukemic disease that is often present in patients with MCL, concludes Till.